Ascendis and BioMarin agree global Yuviwel patent settlement and licence

The binding term sheet resolves litigation between Ascendis Pharma and BioMarin while granting Ascendis a worldwide licence covering YUVIWEL and other navepegritide-related products.

BioMarin has agreed to grant Ascendis a non-exclusive, worldwide, royalty-bearing licence allowing it to continue researching, developing, manufacturing and commercialising navepegritide-related products without restriction.

Ascendis will pay BioMarin royalties equal to 20% of US net sales and 18% of net sales in the European Union, South Korea and Brazil from first commercial sale through 20 May 2030, while the companies will dismiss their respective proceedings.

Field	Content
Alert Type	Industry Update
Companies	Ascendis Pharma; BioMarin Pharmaceutical
Agreement Type	Global settlement and licence agreement
Product	YUVIWEL (navepegritide)
Therapy Area	Achondroplasia and skeletal dysplasias
Technology or Modality	C-type natriuretic peptide prodrug
Geography	Global
What Happened	On 31 August 2026, Ascendis Pharma and BioMarin entered into a binding term sheet setting out the terms of a global settlement and licence agreement related to YUVIWEL and other navepegritide-related products. The agreement is intended to resolve litigation and disputes between the companies.
Licence Terms	BioMarin will grant Ascendis a non-exclusive, worldwide, royalty-bearing licence allowing Ascendis to continue researching, developing, manufacturing and commercialising navepegritide-related products without restriction.
Royalty Terms	Ascendis will pay BioMarin royalties equal to 20% of US net sales and 18% of net sales in the European Union, South Korea and Brazil from first commercial sale in each territory through 20 May 2030.
Why It Matters	The settlement removes a material intellectual-property dispute surrounding Ascendis' navepegritide franchise and provides a defined framework for continued global development and commercialisation.
Supporting Context	BioMarin has also agreed to waive certain regulatory rights and exclusivities, dismiss proceedings and provide a covenant not to sue relating to the covered intellectual property.
Potential Impact	Resolution of the dispute could reduce legal uncertainty around YUVIWEL and allow Ascendis to focus on commercial expansion and further development of navepegritide-related products.
Key Takeaway	Ascendis has secured a worldwide licence and global settlement with BioMarin covering YUVIWEL and navepegritide-related products in exchange for defined royalty payments through May 2030.
What to Watch	Execution of the definitive settlement agreement and the commercial trajectory of YUVIWEL across the covered markets.
Primary Source	Ascendis Pharma
Relevant Date	31 August 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector

• Contact us on: support@nuaxia.com